239 related articles for article (PubMed ID: 8450033)
1. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
2. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.
Eldering E; Huijbregts CC; Nuijens JH; Hack CE
Behring Inst Mitt; 1993 Dec; (93):125-30. PubMed ID: 8172559
[No Abstract] [Full Text] [Related]
3. Role of the P6-P3' region of the serpin reactive loop in the formation and breakdown of the inhibitory complex.
Plotnick MI; Schechter NM; Wang ZM; Liu X; Rubin H
Biochemistry; 1997 Nov; 36(47):14601-8. PubMed ID: 9398179
[TBL] [Abstract][Full Text] [Related]
4. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
5. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
de Agostini A; Patston PA; Marottoli V; Carrel S; Harpel PC; Schapira M
J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
[TBL] [Abstract][Full Text] [Related]
6. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
Zahedi R; MacFarlane RC; Wisnieski JJ; Davis AE
J Immunol; 2001 Aug; 167(3):1500-6. PubMed ID: 11466370
[TBL] [Abstract][Full Text] [Related]
7. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
[TBL] [Abstract][Full Text] [Related]
8. Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.
Schapira M; Ramus MA; Waeber B; Brunner HR; Jallat S; Carvallo D; Roitsch C; Courtney M
J Clin Invest; 1987 Aug; 80(2):582-5. PubMed ID: 3497179
[TBL] [Abstract][Full Text] [Related]
9. Structure and function of C1 inhibitor.
Davis AE
Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
[TBL] [Abstract][Full Text] [Related]
10. Characterization of recombinant C1 inhibitor P1 variants.
Eldering E; Huijbregts CC; Lubbers YT; Longstaff C; Hack CE
J Biol Chem; 1992 Apr; 267(10):7013-20. PubMed ID: 1551909
[TBL] [Abstract][Full Text] [Related]
11. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
Zahedi R; Wisnieski J; Davis AE
J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
[TBL] [Abstract][Full Text] [Related]
12. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
Gils A; Knockaert I; Declerck PJ
Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the serpin domain of C1 inhibitor.
Coutinho M; Aulak KS; Davis AE
J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1-antitrypsin Pittsburgh (Met358-->Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation.
Wachtfogel YT; Bischoff R; Bauer R; Hack CE; Nuijens JH; Kucich U; Niewiarowski S; Edmunds LH; Colman RW
Thromb Haemost; 1994 Dec; 72(6):843-7. PubMed ID: 7740452
[TBL] [Abstract][Full Text] [Related]
15. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
Brower MS; Harpel PC
J Biol Chem; 1982 Aug; 257(16):9849-54. PubMed ID: 6980881
[TBL] [Abstract][Full Text] [Related]
17. Expression of functional human C1 inhibitor in COS cells.
Eldering E; Nuijens JH; Hack CE
J Biol Chem; 1988 Aug; 263(24):11776-9. PubMed ID: 2841334
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding.
Rossi V; Bally I; Ancelet S; Xu Y; Frémeaux-Bacchi V; Vivès RR; Sadir R; Thielens N; Arlaud GJ
J Immunol; 2010 May; 184(9):4982-9. PubMed ID: 20351192
[TBL] [Abstract][Full Text] [Related]
19. Chymotrypsin inhibitory activity of normal C1-inhibitor and a P1 Arg to His mutant: evidence for the presence of overlapping reactive centers.
Aulak KS; Davis AE; Donaldson VH; Harrison RA
Protein Sci; 1993 May; 2(5):727-32. PubMed ID: 8495195
[TBL] [Abstract][Full Text] [Related]
20. Elastase inhibitor from mammalian neutrophil cytosol.
Korzus E; Dubin A; Potempa J; Travis J
Biomed Biochim Acta; 1991; 50(4-6):687-90. PubMed ID: 1801744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
